KCNV2-Associated Retinopathy: Detailed Retinal Phenotype and Structural Endpoints-KCNV2 Study Group Report 2.
Journal
American journal of ophthalmology
ISSN: 1879-1891
Titre abrégé: Am J Ophthalmol
Pays: United States
ID NLM: 0370500
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
10
08
2020
revised:
02
03
2021
accepted:
03
03
2021
pubmed:
20
3
2021
medline:
27
1
2022
entrez:
19
3
2021
Statut:
ppublish
Résumé
To describe the detailed retinal phenotype of KCNV2-associated retinopathy. Multicenter international retrospective case series. Review of retinal imaging including fundus autofluorescence (FAF) and optical coherence tomography (OCT), including qualitative and quantitative analyses. Three distinct macular FAF features were identified: (1) centrally increased signal (n = 35, 41.7%), (2) decreased autofluorescence (n = 27, 31.1%), and (3) ring of increased signal (n = 37, 44.0%). Five distinct FAF groups were identified based on combinations of those features, with 23.5% of patients changing the FAF group over a mean (range) follow-up of 5.9 years (1.9-13.1 years). Qualitative assessment was performed by grading OCT into 5 grades: (1) continuous ellipsoid zone (EZ) (20.5%); (2) EZ disruption (26.1%); (3) EZ absence, without optical gap and with preserved retinal pigment epithelium complex (21.6%); (4) loss of EZ and a hyporeflective zone at the foveola (6.8%); and (5) outer retina and retinal pigment epithelium complex loss (25.0%). Eighty-six patients had scans available from both eyes, with 83 (96.5%) having the same grade in both eyes, and 36.1% changed OCT grade over a mean follow-up of 5.5 years. The annual rate of outer nuclear layer thickness change was similar for right and left eyes. KCNV2-associated retinopathy is a slowly progressive disease with early retinal changes, which are predominantly symmetric between eyes. The identification of a single OCT or FAF measurement as an endpoint to determine progression that applies to all patients may be challenging, although outer nuclear layer thickness is a potential biomarker. Findings suggest a potential window for intervention until 40 years of age.
Identifiants
pubmed: 33737031
pii: S0002-9394(21)00117-3
doi: 10.1016/j.ajo.2021.03.004
pmc: PMC8710866
pii:
doi:
Substances chimiques
KCNV2 protein, human
0
Potassium Channels, Voltage-Gated
0
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-11Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NEI NIH HHS
ID : P30 EY010572
Pays : United States
Organisme : Department of Health
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 099173/Z/12/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 206619/Z/17/Z
Pays : United Kingdom
Organisme : NEI NIH HHS
ID : P30 EY010572
Pays : United States
Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Références
Am J Ophthalmol. 2017 Jun;178:18-26
pubmed: 28322733
Eye (Lond). 2015 Sep;29(9):1131-40
pubmed: 26113499
Invest Ophthalmol Vis Sci. 2019 Jan 2;60(1):383-396
pubmed: 30682209
Br J Ophthalmol. 2012 Feb;96(2):213-7
pubmed: 21558291
Nippon Ganka Gakkai Zasshi. 2013 Aug;117(8):629-40
pubmed: 24063160
Invest Ophthalmol Vis Sci. 2014 Feb 10;55(2):832-40
pubmed: 24370833
Transl Vis Sci Technol. 2019 Oct 2;8(5):21
pubmed: 31602346
Curr Eye Res. 2020 Oct;45(10):1257-1264
pubmed: 32108519
Retina. 2010 Jan;30(1):51-62
pubmed: 19952985
Retin Cases Brief Rep. 2018 Fall;12 Suppl 1:S59-S62
pubmed: 29210963
Retina. 2016 Jun;36(6):1216-21
pubmed: 26583307
Am J Ophthalmol. 2008 Jun;145(6):1099-106
pubmed: 18400204
JAMA Ophthalmol. 2017 Nov 1;135(11):1232-1241
pubmed: 29049437
Ophthalmology. 2013 Nov;120(11):e79-80
pubmed: 24182571
Invest Ophthalmol Vis Sci. 2019 Jun 3;60(7):2631-2640
pubmed: 31237654
Br J Ophthalmol. 2018 Aug;102(8):1028-1035
pubmed: 29141905
Invest Ophthalmol Vis Sci. 2011 Sep 29;52(10):7640-6
pubmed: 21873669
Br J Ophthalmol. 2019 Jan 24;:
pubmed: 30679166
Retina. 2013 Jan;33(1):5-12
pubmed: 23263253
Ophthalmology. 2016 Apr;123(4):817-28
pubmed: 26786511
Am J Ophthalmol. 2018 Feb;186:1-9
pubmed: 29126757
Am J Ophthalmol. 2021 May;225:95-107
pubmed: 33309813
Ophthalmic Genet. 2007 Sep;28(3):135-42
pubmed: 17896311
Invest Ophthalmol Vis Sci. 2020 Apr 9;61(4):47
pubmed: 32347917
JAMA Ophthalmol. 2017 Jul 1;135(7):687-695
pubmed: 28542697
PLoS One. 2012;7(10):e46762
pubmed: 23077521
Transl Vis Sci Technol. 2019 Mar 1;8(2):1
pubmed: 30834176
Invest Ophthalmol Vis Sci. 2018 Dec 3;59(15):5735-5744
pubmed: 30513534
Invest Ophthalmol Vis Sci. 2018 Jun 1;59(7):3037-3040
pubmed: 30025118
Ophthalmic Genet. 2020 Jun;41(3):208-215
pubmed: 32441199
Doc Ophthalmol. 2008 Mar;116(2):79-89
pubmed: 17985165
Invest Ophthalmol Vis Sci. 2015 Feb 09;56(2):918-31
pubmed: 25667399
Ophthalmology. 2020 Oct;127(10):1384-1394
pubmed: 32423767
JAMA Ophthalmol. 2013 Nov;131(11):1482-5
pubmed: 24029832
Retina. 2020 Sep;40(9):1829-1837
pubmed: 31725702
Ann Eye Sci. 2020 Sep;5:
pubmed: 33928237
Br J Ophthalmol. 2005 Mar;89(3):332-9
pubmed: 15722315
Invest Ophthalmol Vis Sci. 2016 Aug 1;57(10):3984-95
pubmed: 27479814
Invest Ophthalmol Vis Sci. 2013 Jan 30;54(1):898-908
pubmed: 23221069
Am J Ophthalmol. 2020 Mar;211:159-175
pubmed: 31812472
Mol Vis. 2013 Jul 20;19:1580-90
pubmed: 23885164
Invest Ophthalmol Vis Sci. 2019 Dec 2;60(15):5112-5123
pubmed: 31826238